Blog

Societies

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Photo taken from Grainne O’Kane/X

Jun 5, 2024, 13:27

Grainne O’Kane: GIANT trial in more than 70 years/ vulnerable PDAC at ASCO24

Grainne O’Kane, Medical Oncologist and Clinical Research Fellow at Trinity St. James’s Cancer Institute, shared a post on X:

“GIANT trial in more than 70 years/vulnerable Pancreatic ductal adenocarcinoma (PDAC) American Society of Clinical Oncology 2024 (ASCO24) as by geriatric assess.

Important to remember most on PDAC trials less than 70 years.
Dose modified Gemcitabine plus nab-Paclitaxel (GnP) versus 5‐Fluorouracil (5FU) liposomal irinotecan.
Sobering med Overall Survival (OS) by Intention-To-Treat (ITT) 4.7 versus 4.4 months.
Need to identify who can benefit and discuss with patients.”

GIANT trial

Source: Grainne O’Kane/X

5‐Fluorouracil ASCO ASCO24 cancer Gemcitabine plus nab-Paclitaxel (GnP) Grainne O’Kane OncoDaily Oncology Overall survival (OS) pancreatic ductal adenocarcinoma (PDAC)

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

Former Disney CEO Bob Chapek Appointed Senior Adviser at SCAN Group

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage